152 related articles for article (PubMed ID: 31943533)
21. Network-Based Genetic Profiling Reveals Cellular Pathway Differences Between Follicular Thyroid Carcinoma and Follicular Thyroid Adenoma.
Hossain MA; Asa TA; Rahman MM; Uddin S; Moustafa AA; Quinn JMW; Moni MA
Int J Environ Res Public Health; 2020 Feb; 17(4):. PubMed ID: 32093341
[TBL] [Abstract][Full Text] [Related]
22.
Paulsson JO; Mu N; Shabo I; Wang N; Zedenius J; Larsson C; Juhlin CC
Endocr Relat Cancer; 2018 Jul; 25(7):723-733. PubMed ID: 29692346
[TBL] [Abstract][Full Text] [Related]
23. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
[TBL] [Abstract][Full Text] [Related]
24. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
[TBL] [Abstract][Full Text] [Related]
25. Predominant
Lee YA; Im SW; Jung KC; Chung EJ; Shin CH; Kim JI; Park YJ
Thyroid; 2020 Aug; 30(8):1120-1131. PubMed ID: 32228164
[No Abstract] [Full Text] [Related]
26. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma.
Mosrati MA; Malmström A; Lysiak M; Krysztofiak A; Hallbeck M; Milos P; Hallbeck AL; Bratthäll C; Strandéus M; Stenmark-Askmalm M; Söderkvist P
Oncotarget; 2015 Jun; 6(18):16663-73. PubMed ID: 26143636
[TBL] [Abstract][Full Text] [Related]
27. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
[TBL] [Abstract][Full Text] [Related]
28. Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer.
Panebianco F; Nikitski AV; Nikiforova MN; Nikiforov YE
Cancer Med; 2019 Oct; 8(13):5831-5839. PubMed ID: 31408918
[TBL] [Abstract][Full Text] [Related]
29. 5hmC Immunohistochemistry: A Predictor of
Hysek M; Hellgren SL; Condello V; Xu Y; Larsson C; Zedenius J; Juhlin CC
J Histochem Cytochem; 2023 Aug; 71(8):451-458. PubMed ID: 37486076
[TBL] [Abstract][Full Text] [Related]
30. Differentiation of follicular thyroid adenoma from carcinoma by means of gene expression profiling with adapter-tagged competitive polymerase chain reaction.
Taniguchi K; Takano T; Miyauchi A; Koizumi K; Ito Y; Takamura Y; Ishitobi M; Miyoshi Y; Taguchi T; Tamaki Y; Kato K; Noguchi S
Oncology; 2005; 69(5):428-35. PubMed ID: 16319515
[TBL] [Abstract][Full Text] [Related]
31. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.
Ko E; Seo HW; Jung ES; Kim BH; Jung G
Oncotarget; 2016 Jan; 7(1):684-99. PubMed ID: 26575952
[TBL] [Abstract][Full Text] [Related]
32. Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms.
Proietti A; Sartori C; Macerola E; Borrelli N; Materazzi G; Vitti P; Basolo F
Virchows Arch; 2017 Dec; 471(6):769-773. PubMed ID: 28975450
[TBL] [Abstract][Full Text] [Related]
33. Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status.
Park H; Heo J; Ki CS; Shin JH; Oh YL; Son YI; Kim JS; Kim SW; Chung JH; Kim TY; Kim TH; Kim JH
Ann Surg Oncol; 2023 May; 30(5):2916-2925. PubMed ID: 36637642
[TBL] [Abstract][Full Text] [Related]
34. TERT promoter mutations in thyroid cancer.
Liu R; Xing M
Endocr Relat Cancer; 2016 Mar; 23(3):R143-55. PubMed ID: 26733501
[TBL] [Abstract][Full Text] [Related]
35. TERT, HRAS, and EIF1AX Mutations in a Patient with Follicular Adenoma.
Topf MC; Wang ZX; Tuluc M; Pribitkin EA
Thyroid; 2018 Jun; 28(6):815-817. PubMed ID: 29669480
[TBL] [Abstract][Full Text] [Related]
36. A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!
Juhlin CC
Scand J Surg; 2020 Sep; 109(3):187-192. PubMed ID: 31131695
[TBL] [Abstract][Full Text] [Related]
37. Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings.
Jeong SH; Hong HS; Kwak JJ; Lee EH
J Endocrinol Invest; 2015 Aug; 38(8):849-57. PubMed ID: 25999051
[TBL] [Abstract][Full Text] [Related]
38. Loss of estrogen receptor Beta expression in follicular thyroid carcinoma predicts poor outcome.
Heikkilä A; Hagström J; Mäenpää H; Louhimo J; Siironen P; Heiskanen I; Haglund C; Arola J
Thyroid; 2013 Apr; 23(4):456-65. PubMed ID: 23106428
[TBL] [Abstract][Full Text] [Related]
39. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.
Shi X; Liu R; Qu S; Zhu G; Bishop J; Liu X; Sun H; Shan Z; Wang E; Luo Y; Yang X; Zhao J; Du J; El-Naggar AK; Teng W; Xing M
J Clin Endocrinol Metab; 2015 Apr; 100(4):E632-7. PubMed ID: 25584719
[TBL] [Abstract][Full Text] [Related]
40. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
